| Trial ID: | L0116 |
| Source ID: | NCT01343641
|
| Associated Drug: |
Mk-0677
|
| Title: |
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Kidney Disease
|
| Interventions: |
DRUG: MK-0677|DRUG: Placebo
|
| Outcome Measures: |
Primary: Lean body weight., N/A - Study Withdrawn, 12 months | Secondary: Cytokine levels, N/A - Study Withdrawn, 12 months|Hormone levels, N/A - Study Withdrawn, 12 months|Nutritional status, N/A - Study Withdrawn, 12 months|Quality of life, N/A - Study Withdrawn, 12 months|Physical function, N/A - Study Withdrawn, 12 months
|
| Sponsor/Collaborators: |
Sponsor: University of Virginia | Collaborators: National Institutes of Health (NIH)|Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE
|
| Start Date: |
2009-03
|
| Completion Date: |
2010-04
|
| Results First Posted: |
|
| Last Update Posted: |
2018-05-14
|
| Locations: |
University of Virginia, Charlottesville, Virginia, 22908, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01343641
|
